// you're reading...


The basic and clinical related research concerning IC2 and its autoantigen move from the Panum Institute, Department of Biomedical Sciences, to the new modern Copenhagen Biocenter at The Bartholin Institute

By action from September 1st 2010, the basic and clinically aiming research associated with the monoclonal autoantibody IC2 and its unique autoantigen specific on the surface of the pancreatic beta-cell, will move from University of Copenhagen, Department of Biomedical Sciences, to the new and modern Copenhagen Biocenter,  and be part of The Bartholin Institute, which is a research unit under the University Hospital, Rigshospitalet with a long track of research in autoimmune diabetes and pathology..

The Bartholin Institut home excellent fascilities for flow cytometric analysis, confocal laser microscopy, cell biology, histochemistry, immunocytochemistry, immunology, immunochemistry plus molecular biology. We look forward to a fruitful collaboration.

Welcome to ImmunoSigns

ImmunoSigns is a Biotech company founded in 1996. We offer you help in project management and R&D activities within biotechnology and immunodetection.

The core competance of ImmunoSigns is development and production of polyclonal and monoclonal antibodies and design and production of novel immunoassays and diagnostic kits, especially within the clinical area of diabetes and obesity.

Shopping Cart